Delergotrile

Delergotrile
Clinical data
Other names	CM 29-712; CM-29712; CM29-712; 6-Methylergoline-8α-acetonitrile; 6-Methyl-8α-(cyanomethyl)ergoline
Drug class	Dopamine receptor agonist; Antiparkinsonian agent
ATC code	None;
Identifiers
	IUPAC name 2-[(6aR,9R,10aR)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]acetonitrile;
CAS Number	59091-65-5;
PubChem CID	10264850;
ChemSpider	8440329;
UNII	3U2FEE7NXX;
ChEMBL	ChEMBL174095;
CompTox Dashboard (EPA)	DTXSID101024216 ;
Chemical and physical data
Formula	C17H19N3
Molar mass	265.360 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C[C@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CC#N;
	InChI InChI=1S/C17H19N3/c1-20-10-11(5-6-18)7-14-13-3-2-4-15-17(13)12(9-19-15)8-16(14)20/h2-4,9,11,14,16,19H,5,7-8,10H2,1H3/t11-,14+,16+/m0/s1; Key:LBMFWYCMCHRLBU-SGIREYDYSA-N;

Delergotrile (INNTooltip International Nonproprietary Name; developmental code name CM 29-712), also known as 6-methylergoline-8α-acetonitrile, is a dopamine receptor agonist of the ergoline family described as an antiparkinsonian agent which was never marketed.¹ It is an analogue of lergotrile (LY-79907).¹

The drug shows high affinity for the dopamine D₂ receptor (K_i = 34 nM).²³ In addition to dopamine receptors, delergotrile shows affinity for the serotonin 5-HT₁ receptor (K_0.5 = 2.0 nM) and for the serotonin 5-HT₂ receptor (K_i = 57 nM),²³ as well as for the α₁- and α₂-adrenergic receptors.⁴ The drug appears to be an agonist of both dopamine D₁ and to a lesser extent D₂ receptors.⁵ Due to its dopamine receptor agonism, delergotrile produces antiparkinsonian-like effects, induces changes in locomotor activity and stereotypy, and reverses reserpine-induced akinesia in rodents.⁶⁵ It also produces effects consistent with weak blockade of α-adrenergic receptors in rodents.⁶³⁵⁷

Delergotrile was first described in the literature by 1976.¹⁸ It was developed by Sandoz.¹⁸

References

Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. ISBN 978-1-4757-2085-3. Retrieved 6 May 2026.
Beart PM, McDonald D, Cincotta M, de Vries DJ, Gundlach AL (1986). "Selectivity of some ergot derivatives for 5-HT1 and 5-HT2 receptors of rat cerebral cortex". General Pharmacology. 17 (1): 57–62. doi:10.1016/0306-3623(86)90011-x. PMID 3949149.
Fuxe K, Ogren SO, Agnati LF, Andersson K, Hall H, Köhler C, et al. (1980). "Central monoamine synapses as sites of action for ergot drugs". Advances in Biochemical Psychopharmacology. 23: 41–62. PMID 6104914.
McPherson GA, Beart PM (August 1983). "The selectivity of some ergot derivatives for alpha 1 and alpha 2-adrenoceptors of rat cerebral cortex". European Journal of Pharmacology. 91 (4): 363–369. doi:10.1016/0014-2999(83)90159-0. PMID 6311586.
Markstein R (1981). "Neurochemical effects of some ergot derivatives: a basis for their antiparkinson actions". Journal of Neural Transmission. 51 (1–2): 39–59. doi:10.1007/BF01664004. PMID 6267192.
Vigouret JM, Bürki HR, Jaton AL, Züger PE, Loew DM (1978). "Neurochemical and neuropharmacological investigations with four ergot derivatives: bromocriptine, dihydroergotoxine, CF 25-397 and CM 29-712". Pharmacology. 16 Suppl 1: 156–173. doi:10.1159/000136817. PMID 565520.
McPherson GA (January 1984). "In vitro selectivity of lisuride and other ergot derivatives for alpha 1- and alpha 2-adrenoceptors". European Journal of Pharmacology. 97 (1–2): 151–155. doi:10.1016/0014-2999(84)90525-9. PMID 6321208.
Jaton AL, Loew DM, Vigouret JM (March 1978). "A comparison of apomorphine, bromocriptine and Sandoz CM 29-712 (6-methyl-8a-cyanomethyl-ergoline-l) in four different turning models in the rat [proceedings]". British Journal of Pharmacology. 62 (3): 395P. PMC 1668167. PMID 565235.

[Elks2014-1] Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. ISBN 978-1-4757-2085-3. Retrieved 6 May 2026.

[BeartMcDonaldCincotta1986-2] Beart PM, McDonald D, Cincotta M, de Vries DJ, Gundlach AL (1986). "Selectivity of some ergot derivatives for 5-HT1 and 5-HT2 receptors of rat cerebral cortex". General Pharmacology. 17 (1): 57–62. doi:10.1016/0306-3623(86)90011-x. PMID 3949149.

[FuxeOgrenAgnati1980-3] Fuxe K, Ogren SO, Agnati LF, Andersson K, Hall H, Köhler C, et al. (1980). "Central monoamine synapses as sites of action for ergot drugs". Advances in Biochemical Psychopharmacology. 23: 41–62. PMID 6104914.

[McPhersonBeart1983-4] McPherson GA, Beart PM (August 1983). "The selectivity of some ergot derivatives for alpha 1 and alpha 2-adrenoceptors of rat cerebral cortex". European Journal of Pharmacology. 91 (4): 363–369. doi:10.1016/0014-2999(83)90159-0. PMID 6311586.

[Markstein1981-5] Markstein R (1981). "Neurochemical effects of some ergot derivatives: a basis for their antiparkinson actions". Journal of Neural Transmission. 51 (1–2): 39–59. doi:10.1007/BF01664004. PMID 6267192.

[VigouretBürkiJaton1978-6] Vigouret JM, Bürki HR, Jaton AL, Züger PE, Loew DM (1978). "Neurochemical and neuropharmacological investigations with four ergot derivatives: bromocriptine, dihydroergotoxine, CF 25-397 and CM 29-712". Pharmacology. 16 Suppl 1: 156–173. doi:10.1159/000136817. PMID 565520.

[McPherson1984-7] McPherson GA (January 1984). "In vitro selectivity of lisuride and other ergot derivatives for alpha 1- and alpha 2-adrenoceptors". European Journal of Pharmacology. 97 (1–2): 151–155. doi:10.1016/0014-2999(84)90525-9. PMID 6321208.

[JatonLoewVigouret1978-8] Jaton AL, Loew DM, Vigouret JM (March 1978). "A comparison of apomorphine, bromocriptine and Sandoz CM 29-712 (6-methyl-8a-cyanomethyl-ergoline-l) in four different turning models in the rat [proceedings]". British Journal of Pharmacology. 62 (3): 395P. PMC 1668167. PMID 565235.

1

2

3

4

5

6

7

8

See also

References